Max Healthcare Institute Ltd
Max Healthcare Institute Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Max Healthcare reported a strong 27% year-on-year revenue growth in Q1 FY '26, driven by successful hospital acquisitions and integrations. - Existing units showed a 16% revenue growth, with like-for-like ARPOB growth of 5% year-on-year. - Occupancy in base hospitals is around 80%, indicating capacity constraints; growth is expected from new bed additions. - Approximately 1,000 brownfield and 500 greenfield beds are expected to be commissioned in FY '26, driving volume growth. - New hospitals like Lucknow and Nagpur are contributing significantly, with Lucknow showing 97% revenue growth year-on-year. - Noida and Dwarka facilities are expected to see acceleration in performance post-integration. - International patient revenue grew by 32% year-on-year, bolstered by expanded marketing and new geographies. - Net debt poised to increase by Rs. Max Healthcare reported 27% YoY growth in revenue and 23% growth in operating EBITDA in Q1 FY26, marking 19 consecutive quarters of YoY growth, indicating strong ongoing momentum. - Management expects continued EBITDA margin improvement in FY26, driven by better occupancy and utilization across hospitals, despite some margin pressures from superior clinical and payor mix. - EBITDA per bed and Return on Capital Employed (ROCE) are highlighted as more relevant metrics, expected to improve with new expansions and acquisitions. - New brownfield and greenfield bed capacities (~1,000 brownfield and 500 greenfield beds) are expected to start commissioning, further driving revenue and earnings growth. - Net debt is expected to increase modestly by Rs.
From Max Healthcare Institute Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Max Healthcare reported a strong 27% year-on-year revenue growth in Q1 FY '26, driven by successful hospital acquisitions and integrations.
- Existing units showed a 16% revenue growth, with like-for-like ARPOB growth of 5% year-on-year.
- Occupancy in base hospitals is around 80%, indicating capacity constraints; growth is expected from new bed additions.
- Approximately 1,000 brownfield and 500 greenfield beds are expected to be commissioned in FY '26, driving volume growth.
- New hospitals like Lucknow and Nagpur are contributing significantly, with Lucknow showing 97% revenue growth year-on-year.
- Noida and Dwarka facilities are expected to see acceleration in performance post-integration.
- International patient revenue grew by 32% year-on-year, bolstered by expanded marketing and new geographies.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Max Healthcare Institute Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Max Healthcare is actively expanding with ongoing and planned projects including:
- 268 beds at Nanavati Phase 1, commissioning basements to third floors, starting soon.
- 400 beds at Max Smart, Saket Complex, with phased commissioning expected by end Q2 FY '26.
- Expansion at Max Lucknow to increase capacity from 413 to 520 beds by FY end.
- 500 beds under construction at Sector 56 Gurgaon, expected commissioning by FY end.
- 100 beds at Max Nagpur, awaiting environmental clearance; project to complete within 24 months.
- 397 beds at Patparganj, environmental clearance received, construction underway.
- 550 beds at Max Vikrant, Saket Complex, pending Forest Department clearance.
- 400 beds at Zirakpur, Mohali under fast construction, expected completion in 24 months.
- 140 beds expansion at Max Vaishali, demolition underway, completion in 30 months.
- New 130-bed built-to-suit hospital in Dehradun, Board-approved lease agreement.
- Rs. 435 crores deployed towards capacity expansions and upgrades in Q1 FY '26.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Max Healthcare Institute Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Max Healthcare has several ongoing expansion projects contributing to its order book:
- 400 beds at Zirakpur, Mohali: Approvals received; site work progressing; expected completion within 24 months.
- 140 beds at Max Vaishali: Demolition underway; building plans being filed; expected completion within 30 months.
- 500 beds at Thane: Master plan finalizing; detailed drawings being prepared; submissions starting by end of the quarter.
- 250 beds at Pitampura, Delhi: Drawings submitted; site cleanup completed; construction to start upon approvals.
- 268 beds at Nanavati Phase 1: Advanced commissioning stages.
- 400 beds at Max Smart, Saket: Progressing; phased commissioning expected by end of Q2 FY '26.
- Max Lucknow expansion: Increasing capacity from 413 to 520 beds by FY end.
- 500 beds at Sector 56 Gurgaon: Structural work in progress; commissioning expected by FY end.
- 100 beds at Max Nagpur: Environmental clearance awaited; project expected completion in 24 months.
- 397 beds at Patparganj: Environmental clearance received; work in progress.
2 more points management made on order book & pipeline
Max Healthcare Institute Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.1K Cr, net profit ₹342 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Max Healthcare's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Aster DM Quality (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
- Syngene International Ltd (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
- Yatharth Hospit. (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Frequently Asked Questions
What were Max Healthcare Institute Ltd Q1 FY26 results?
Max Healthcare reported a strong 27% year-on-year revenue growth in Q1 FY '26, driven by successful hospital acquisitions and integrations. - Existing units showed a 16% revenue growth, with like-for-like ARPOB growth of 5% year-on-year. - Occupancy in base hospitals is around 80%, indicating capacity constraints; growth is expected from new bed additions. - Approximately 1,000 brownfield and 500 greenfield beds are expected to be commissioned in FY '26, driving volume growth. - New hospitals like Lucknow and Nagpur are contributing significantly, with Lucknow showing 97% revenue growth year-on-year. - Noida and Dwarka facilities are expected to see acceleration in performance post-integration. - International patient revenue grew by 32% year-on-year, bolstered by expanded marketing and new geographies. - Net debt poised to increase by Rs. Max Healthcare reported 27% YoY growth in revenue and 23% growth in operating EBITDA in Q1 FY26, marking 19 consecutive quarters of YoY growth, indicating strong ongoing momentum. - Management expects continued EBITDA margin improvement in FY26, driven by better occupancy and utilization across hospitals, despite some margin pressures from superior clinical and payor mix. - EBITDA per bed and Return on Capital Employed (ROCE) are highlighted as more relevant metrics, expected to improve with new expansions and acquisitions. - New brownfield and greenfield bed capacities (~1,000 brownfield and 500 greenfield beds) are expected to start commissioning, further driving revenue and earnings growth. - Net debt is expected to increase modestly by Rs.
What is Max Healthcare Institute Ltd share price analysis?
Max Healthcare Institute Ltd currently shows a neutral. The stock trades at a P/E of 65.6 with a market cap of ₹98,161 Cr. Investors should review the full earnings analysis for detailed insights.
Is Max Healthcare Institute Ltd planning capital expenditure?
Max Healthcare is actively expanding with ongoing and planned projects including: - 268 beds at Nanavati Phase 1, commissioning basements to third floors, starting soon. - 400 beds at Max Smart, Saket Complex, with phased commissioning expected by end Q2 FY '26. - Expansion at Max Lucknow to increase capacity from 413 to 520 beds by FY end. - 500 beds under construction at Sector 56 Gurgaon, expected commissioning by FY end. - 100 beds at Max Nagpur, awaiting environmental clearance; project to complete within 24 months. - 397 beds at Patparganj, environmental clearance received, construction underway. - 550 beds at Max Vikrant, Saket Complex, pending Forest Department clearance. - 400 beds at Zirakpur, Mohali under fast construction, expected completion in 24 months. - 140 beds expansion at Max Vaishali, demolition underway, completion in 30 months. - New 130-bed built-to-suit hospital in Dehradun, Board-approved lease agreement. - Rs.
Keep Max Healthcare Institute Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
